Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Depression 2Neoplasms 1Neoplasm Metastasis 1Hospice 1Hematopoietic and Lymphatic System Neoplasm 1Hematologic Neoplasms 1Emotional Regulation 1Breast Neoplasms 1Anxiety Disorders 1Advanced Cancer 1

Interventions

pembrolizumab 105Specimen Handling 55Magnetic Resonance Spectroscopy 48Biopsy 47Nivolumab 40Paclitaxel 35Gemcitabine 30Radiosurgery 29Carboplatin 28Irinotecan 22Ipilimumab 22Cyclophosphamide 22Cisplatin 22trastuzumab deruxtecan 21Leucovorin 19Capecitabine 19Fluorouracil 18Cetuximab 18Bevacizumab 18130-nm albumin-bound paclitaxel 18Pemetrexed 17Fulvestrant 17Drug Therapy 16Docetaxel 16Taxes 15Oxaliplatin 15olaparib 14abemaciclib 14Radiotherapy 14palbociclib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Psychotherapy × 1 year × Clear all
NCT07336238 2026-05-29

Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies

University of Washington

Phase 2 Recruiting
18 enrolled

Anxiety Disorders, Depression, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡